{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:17:45Z","timestamp":1791944265015,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:00:00Z","timestamp":1717804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ejpn-journal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ejpn.2024.06.001","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T22:08:48Z","timestamp":1718230128000},"page":"73-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["2024 update: European consensus statement on gene therapy for spinal muscular atrophy"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1618-7386","authenticated-orcid":false,"given":"Janbernd","family":"Kirschner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Bernert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Butoianu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7126-575X","authenticated-orcid":false,"given":"Liesbeth","family":"De Waele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2867-1685","authenticated-orcid":false,"given":"Aviva","family":"Fattal-Valevski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Haberlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2733-5911","authenticated-orcid":false,"given":"Andrea","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7309-1914","authenticated-orcid":false,"given":"Anna","family":"Kostera-Pruszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Quijano-Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5961-7097","authenticated-orcid":false,"given":"Thomas","family":"Sejersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo F.","family":"Tizzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Ludo","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Zafeiriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7574-1231","authenticated-orcid":false,"given":"Andreas","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejpn.2024.06.001_bib1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/acn3.51281","article-title":"Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study","volume":"8","author":"Annoussamy","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"10.1016\/j.ejpn.2024.06.001_bib2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul. Disord."},{"issue":"15","key":"10.1016\/j.ejpn.2024.06.001_bib3","doi-asserted-by":"crossref","first-page":"e1634","DOI":"10.1212\/WNL.0000000000009248","article-title":"Population-based analysis of survival in spinal muscular atrophy","volume":"94","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ejpn.2024.06.001_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/genes14071377","article-title":"Spinal muscular atrophy treatment in patients identified by newborn screening-A systematic review","volume":"14","author":"Aragon-Gawinska","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.ejpn.2024.06.001_bib5","article-title":"Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom","volume":"37","author":"Gowda","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.ejpn.2024.06.001_bib6","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamapediatrics.2024.0492","article-title":"Clinical effectiveness of newborn screening for spinal muscular atrophy: a nonrandomized controlled trial","volume":"178","author":"Schwartz","year":"2024","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.ejpn.2024.06.001_bib7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpn.2020.07.001","article-title":"European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy","volume":"28","author":"Kirschner","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ejpn.2024.06.001_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejpn.2020.11.003","article-title":"A Decision for Life - treatment decisions in newly diagnosed families with spinal muscular atrophy (SMA)","volume":"30","author":"Gusset","year":"2021","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2024.06.001_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","article-title":"Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study","volume":"6","author":"Weiss","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.ejpn.2024.06.001_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101997","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naive patients with spinal muscular atrophy and following switch from other therapies","volume":"59","author":"Pane","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"7\u20138","key":"10.1016\/j.ejpn.2024.06.001_bib12","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41434-022-00341-6","article-title":"Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study","volume":"30","author":"Bitetti","year":"2023","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.ejpn.2024.06.001_bib13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JND-221560","article-title":"Intrathecal onasemnogene abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: phase I ascending-dose study (STRONG)","volume":"10","author":"Finkel","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"issue":"10","key":"10.1016\/j.ejpn.2024.06.001_bib14","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejpn.2024.06.001_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejpn.2024.06.001_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.51889","article-title":"Combination disease-modifying treatment in spinal muscular atrophy: a proposed classification","author":"Proud","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.ejpn.2024.06.001_bib17","first-page":"1","article-title":"Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study","author":"Chiriboga","year":"2023","journal-title":"Neurol Ther"},{"issue":"4","key":"10.1016\/j.ejpn.2024.06.001_bib18","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/mus.27034","article-title":"Combination molecular therapies for type 1 spinal muscular atrophy","volume":"62","author":"Harada","year":"2020","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.ejpn.2024.06.001_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/dmcn.15286","article-title":"Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening","volume":"65","author":"Dangouloff","year":"2023","journal-title":"Dev. Med. Child Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2024.06.001_bib20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/JND-200593","article-title":"Safety monitoring of gene therapy for spinal muscular atrophy with onasemnogene abeparvovec -A single centre experience","volume":"8","author":"Friese","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"issue":"2","key":"10.1016\/j.ejpn.2024.06.001_bib21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JND-230122","article-title":"Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE registry","volume":"11","author":"Servais","year":"2024","journal-title":"J. Neuromuscul. Dis."},{"issue":"3","key":"10.1016\/j.ejpn.2024.06.001_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijns8030045","article-title":"Modelling the cost-effectiveness and budget impact of a newborn screening program for spinal muscular atrophy and severe combined immunodeficiency","volume":"8","author":"Shih","year":"2022","journal-title":"Int J Neonatal Screen"},{"issue":"4","key":"10.1016\/j.ejpn.2024.06.001_bib23","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s40120-023-00489-2","article-title":"Cost-effectiveness of newborn screening for spinal muscular atrophy in england","volume":"12","author":"Weidlich","year":"2023","journal-title":"Neurol Ther"},{"issue":"6","key":"10.1016\/j.ejpn.2024.06.001_bib24","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","article-title":"Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go","volume":"31","author":"Dangouloff","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ejpn.2024.06.001_bib25","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/jamapediatrics.2024.0489","article-title":"Universal newborn screening for spinal muscular atrophy","volume":"178","author":"Oskoui","year":"2024","journal-title":"JAMA Pediatr."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379824000874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379824000874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T04:58:05Z","timestamp":1721883485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379824000874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":24,"alternative-id":["S1090379824000874"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.06.001","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2024 update: European consensus statement on gene therapy for spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}